Treace Medical Concepts

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Treace Medical Concepts (TMCI) reports stellar revenue growth and innovation plans

Treace Medical Concepts (TMCI) delivered exceptional revenue growth in 2022, exceeding expectations and showcasing strong market positioning. With a focus on innovation, specialized sales strategies, and complementary products, TMCI is poised for continued success. While challenges like sustaining growth exist, the company's strategic investments and upcoming product releases present promising opportunities for future expansion.

Treace Medical Concepts (TMCI) reports robust Q1 growth and raises full-year revenue guidance

Treace Medical Concepts (TMCI) delivered impressive Q1 2023 results, showcasing strong revenue growth and increased market penetration. With raised revenue guidance for the full year and a focus on strategic investments, TMCI is well-positioned for continued success and market expansion.

Treace Medical Concepts reports robust Q2 growth and strategic investments

Treace Medical Concepts (TMCI) delivered strong Q2 results with significant revenue growth, expanded market penetration, and strategic investments in growth initiatives.
While facing a net loss, the company improved adjusted EBITDA and raised full-year revenue guidance, supported by a robust financial position.
Challenges include managing expenses, pricing strategies, and surgeon satisfaction, but opportunities lie in upcoming product launches, reimbursement rates, and surgeon engagement.

Treace Medical Concepts reports strong Q3 revenue growth and outlines future growth strategies

Treace Medical Concepts delivered strong Q3 results with revenue up 23% YoY, despite challenges from soft surgery demand and delayed product launches.
The company's focus on innovation, market expansion, and operational efficiency positions it for future growth and improved financial performance.
While facing short-term challenges, Treace's strategic investments, strong cash position, and product pipeline offer opportunities for sustained growth and market leadership.
Overall, Treace's performance reflects resilience and adaptability in navigating market dynamics, with a clear focus on driving innovation and capturing market opportunities.

Treace Medical Concepts reports robust Q4 earnings and eyes market expansion

Treace Medical Concepts (TMCI) delivered strong financial results in Q4 2023, with revenue growth, positive adjusted EBITDA, and a positive outlook for 2024.
The company's focus on new technologies, market penetration, and efficient sales models positions it well for continued growth and market expansion.
While facing challenges in maintaining gross margins and optimizing sales team productivity, Treace remains optimistic about growth potential and strategic positioning.

Treace Medical Concepts reports robust Q1 growth amidst competitive challenges

Treace Medical Concepts demonstrates strong growth momentum and financial resilience in Q1 2024, driven by product innovation and strategic partnerships.
While facing challenges from increased competition and market pressures, the company remains agile with revised guidance and a focus on cost management.
Opportunities for expansion and differentiation through new product launches and market partnerships position Treace for continued success in the orthopedic medical device sector.

Treace Medical Concepts reports robust Q2 growth and eyes Medicare opportunities

Treace Medical Concepts (TMCI) delivered strong Q2 results and is poised for continued growth with a focus on innovation and market expansion.
While facing challenges in product launch and market competition, the company's commitment to R&D and leveraging regulatory changes provides a solid foundation for future success.
Opportunities in Medicare payment rate increases and new product introductions offer avenues for revenue growth and market leadership in the medical device industry.

Treace Medical Concepts reports Q3 growth, faces patent lawsuit

Treace Medical Concepts showed solid revenue growth in Q3 2024 despite facing a net loss. The company's Nanoplasty system and strategic focus on bunion cases present growth opportunities. Legal challenges and financial losses are key areas of concern.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , Dec. 7, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ: TMCI). Investors who purchased Treace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/tmci.

Bronstein, Gewirtz & Grossman, LLC Announces Treace Medical Concepts, Inc. (TMCI) Investigation

NEW YORK , Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI). Such investors are advised to contact Robert S.

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI

Treace Medical Concepts, Inc. has a key differentiator in its Lapiplasty procedure, with the potential to create a remedial breakthrough. The company showed strong top-line growth in Q3, reaffirming guidance at 43–44% growth at the top line in FY22.

Treace Medical: Differentiated Offering In Lapiplasty Procedure, Rate Buy

Treace Medical Concepts (TMCI) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Treace Medical Concepts (TMCI) is on the Move, Here's Why the Trend Could be Sustainable

PONTE VEDRA, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that its SpeedPlate™ Rapid Compression Implant System (“SpeedPlate™”) has received 510(k) clearance from the FDA to be used for fracture fixation, osteotomy fixation, and joint arthrodesis of the foot and ankle.

Treace Receives FDA 510(k) Clearance for SpeedPlate™ Rapid Compression Implant Technology

Los Angeles, California--(Newsfile Corp. - November 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ: TMCI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Treace Medical Concepts, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ: TMCI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Treace Medical Concepts, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 23, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ: TMCI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Treace Medical Concepts, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace” or “the Company”) (NASDAQ: TMCI) for violations of the securities laws.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Treace Medical Concepts, Inc. and Encourages Investors with Losses to Contact the Firm

PONTE VEDRA, Fla., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced treatment of the first patient in the MTA3D™ Adductoplasty® Clinical Study. The study will evaluate outcomes of the Adductoplasty® Procedure combined with the Lapiplasty® Procedure for patients in need of hallux valgus (bunion) and metatarsus adductus (midfoot) correction surgery. Midfoot deformities may occur in up to 30% of hallux valgus patients.1 , 2

Treace Announces First Patient Treated in MTA3D™ Adductoplasty® Clinical Study

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Treace Medical Concepts, Inc. and Encourages Investors with Losses to Contact the Firm

Atlanta, Georgia--(Newsfile Corp. - November 15, 2022) - Holzer & Holzer, LLC is investigating whether Treace Medical Concepts, Inc. ("Treace Medical" or the "Company") (NASDAQ: TMCI) complied with federal securities laws. On November 15, 2022, Culper Research published a report alleging Treace Medical has driven its business through "aggressive reimbursement practices and deceptive [direct to consumer] marketing.

SHAREHOLDER ALERT: Investigation of Treace Medical Concepts, Inc. (TMCI) Announced By Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations, Gilmartin Group John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Breton Lozada - JPMorgan Andrew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG Rick Wise - Stifel Vivian Cervantes Good afternoon, everyone, and welcome to our Third Quarter 2022 Earnings Conference Call. Participating from the company today will be John Treace, Chief Executive Officer; and Mark Hair, Chief Financial Officer.

Treace Medical Concepts, Inc. (TMCI) Q3 2022 Earnings Call Transcript

PONTE VEDRA, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in the following upcoming investor conferences.

Treace Announces Participation in Upcoming Investor Conferences

PONTE VEDRA, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2022 after the close of trading on Tuesday, November 8, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.

Treace to Report Third Quarter 2022 Financial Results on November 8, 2022

PONTE VEDRA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced the appointment of Lance E. Berry and Jane E. Kiernan to its board of directors, effective October 1, 2022.

Treace Medical Concepts Appoints New Directors

PONTE VEDRA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), announces it will highlight new product innovations at the 2022 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Quebec City, Canada from September 14-17.1

Treace Highlights New Product Innovations at the 2022 AOFAS Scientific Conference

PONTE VEDRA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced an audio poster presentation of the latest interim analysis from the ALIGN3D™ clinical study at the ongoing 2022 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Quebec City, Canada.

Treace Announces Updated ALIGN3D™ Data at the 2022 AOFAS Annual Meeting

Treace Medical Concepts (TMCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Treace Medical Concepts (TMCI): Can Its 8.4% Jump Turn into More Strength?

PONTE VEDRA, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, beginning at approximately 8:35 am ET.

Treace Announces Participation in the Morgan Stanley 20th Annual Global Healthcare Conference

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Andrew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG Operator Good afternoon, and welcome. Thank you for standing by.

Treace Medical Concepts, Inc. (TMCI) CEO John Treace on Q2 2022 Results - Earnings Call Transcript

PONTE VEDRA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced the full commercial release of several new technologies previewed at the February 2022 American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference, including:

Treace Announces Full Commercial Release of New Technologies for Bunion and Related Midfoot Surgery

PONTE VEDRA, Fla., July 25, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced it will host a Surgeon Advisor event at the Nasdaq MarketSite in New York City on Tuesday, September 20, 2022 at 9am ET. The event will include presentations from leading Lapiplasty® and Adductoplasty™ surgeons, as well as remarks from the Treace executive management team. The event will also feature new and recently launched product innovations.

Treace to Host Surgeon Advisor Event on September 20, 2022

PONTE VEDRA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 9, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Treace to Report Second Quarter 2022 Financial Results on August 9, 2022

Treace Medical Concepts (TMCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

News for Treace Medical Concepts Stock (TMCI)